重组胃癌特异性血管生成抑制剂MG-Ad-IP10的研制

批准号:
39970834
项目类别:
面上项目
资助金额:
13.0 万元
负责人:
黄文林
依托单位:
学科分类:
H1819.肿瘤生物治疗
结题年份:
2002
批准年份:
1999
项目状态:
已结题
项目参与者:
刘志国、安华章、何凤田、喻召才、宋保华
国基评审专家1V1指导 中标率高出同行96.8%
结合最新热点,提供专业选题建议
深度指导申报书撰写,确保创新可行
指导项目中标800+,快速提高中标率
微信扫码咨询
中文摘要
为增强重组腺病毒在体内治疗肿瘤的特异性,利用细菌重组系统,通过两次同源重组,将MG单链抗体基因融合表达于病毒颗粒表面的纤毛蛋白上,使重组腺病毒特异性感染MG抗原阳性胃癌细胞,以此为载体将血管抑制基因IP-10引入胃癌细胞并使之高效分泌表达,从≡裥云苹抵琢龈浇苣谄ぃ种莆赴┥ぃ蛑瘟朴τ糜诹俅蔡峁┯幸娴氖笛橐谰荨
英文摘要
To improve the specificity of adenoviral gene therapy in vivo, a bacterial recombination system of adenovirus was used in the experimental therapy of gastric cancer. Two rounds of homologous recombination were carried out in E.coli strain BJ5183。A ScFv fragment of MG antibody was inserted into the fiber prtein of adenovirus, thus the resulting recombinant adenovirus was engineered to specifically infect MG positive gastric cancer cell. Due to the expression of angiostatic molecule, IP-10, in the genome of adenovirus, gastric cancer cells were efficiently inhibited. This experiment provides a preliminary data for the future clinical trial.
专著列表
科研奖励列表
会议论文列表
专利列表
国内基金
海外基金
